公开(公告)号：US20180112192A1

公开(公告)日：2018-04-26

申请号：US15571249

申请日：2016-05-02

Applicant: Andrew Man Chung Wo ,  National Taiwan University ,  Academia Sinica

Inventor： Pan-Chyr Yang ,  Pei-Ying Lin ,  Bo-Tsang Huang

IPC: C12N9/12 ,  A61P35/00 ,  A61K38/45 ,  A61K45/06

CPC classification number: C12N9/12 ,  A61K31/517 ,  A61K31/5377 ,  A61K38/179 ,  A61K38/45 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K14/00 ,  C07K14/71 ,  C07K2319/10 ,  C07K2319/41 ,  C07K2319/43 ,  C12Y207/11001 ,  A61K2300/00

Abstract: The present disclosure includes a PINK1-C-terminal domain (PINK1-CTD) polypeptide that binds to ERBB tyrosine kinase domain (ERBB-TKD) and therefore impedes ERBB from dimerization and activation. The PINK1-CTD polypeptide inhibits, prevents and/or treats ERBB-expressing cancers. The disclosure demonstrates the anti-tumor function of the PINK1-CTD, which provides a new direction for ERBB-expressing cancer therapy.

公开(公告)号：US20180086801A9

公开(公告)日：2018-03-29

申请号：US15328593

申请日：2015-07-24

Applicant: Academia Sinica

Inventor： Benjamin Pang-hsien Tu ,  Rita PY Chen ,  Joseph Jen-Tse Huang ,  Yijuang Chern ,  Yu-Song Jang ,  Xiang-Me Lai ,  Tai-Yan Liao ,  Te-Hsien Kung

IPC: C07K14/47

CPC classification number: C07K14/4711 ,  A61K38/00 ,  C07K14/4703 ,  C07K2319/00

Abstract: Bipartite molecules comprising a peptide affinity moiety and at least one charged moiety and uses thereof in reducing formation of abnormal protein aggregate and treating diseases associated with such abnormal protein aggregate, including neurodegenerative disease characterized by formation of protein aggregates.

公开(公告)号：US09914956B2

公开(公告)日：2018-03-13

申请号：US14422310

申请日：2013-08-16

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Jim-Min Fang ,  Yih-Shyun E. Cheng ,  Charng-Sheng Tsai

IPC: C12Q1/70 ,  C12Q1/40 ,  C12N9/96 ,  C08B37/00 ,  C12Q1/34 ,  C12Q1/04 ,  C07H13/04 ,  C07H13/12 ,  C07H5/00 ,  C12N9/24

CPC classification number: C12Q1/40 ,  C07H5/00 ,  C07H13/04 ,  C07H13/12 ,  C12N9/2402 ,  C12Q1/04 ,  C12Q1/34 ,  C12Q1/70 ,  C12Y302/01018 ,  G01N2333/11

Abstract: Provided herein are novel irreversible sialidase inhibitors. These compounds can be conjugated with a detectable tagging moiety such as azide-annexed biotin via CuAAC for isolation and identification of sialidases. The provided compounds and the corresponding detectable conjugates are useful for detecting sialidase-containing pathogens and imaging in situ sialidase activities under physiological conditions.

公开(公告)号：US20180055887A1

公开(公告)日：2018-03-01

申请号：US15684207

申请日：2017-08-23

Applicant: ACADEMIA SINICA

Inventor： Jean LU ,  Hsiao-Chun HUANG ,  Pei-Lun LAI

IPC: A61K35/28 ,  C12N5/0775

CPC classification number: A61K35/28 ,  A61K35/33 ,  A61K35/545 ,  A61K2035/124 ,  C12N5/0663 ,  C12N5/0664 ,  C12N5/0667 ,  C12N2500/38 ,  C12N2501/065 ,  C12N2501/115 ,  C12N2501/119 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/235 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2502/1358 ,  C12N2502/1382 ,  C12N2506/1307 ,  C12N2506/45

Abstract: The present invention generally relates to a method for preparing induced mesenchymal stem cells (iMSCs) and its applications. The iMSCs, like MSCs, can differentiate into multiple lineages, which may be beneficial for disease treatments. In addition, the present invention also provides a method for improving the MSC's functional characteristics such that the MSCs are more suitable for cell therapy or in vitro applications.

公开(公告)号：US20180030097A1

公开(公告)日：2018-02-01

申请号：US15549457

申请日：2016-01-27

Applicant: Academia Sinica

Inventor： Han-Chung WU ,  Chung-Tao TANG

IPC: C07K14/005 ,  G01N33/569 ,  A61K39/39 ,  C07K16/10 ,  A61K39/12 ,  C12N7/00

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/55505 ,  A61K2039/575 ,  C07K16/1081 ,  C07K2317/34 ,  C07K2317/76 ,  C12N7/00 ,  C12N2770/24122 ,  C12N2770/24123 ,  C12N2770/24134 ,  C12N2770/24151 ,  C12N2770/24171 ,  G01N33/56983 ,  G01N2333/185 ,  G01N2469/20 ,  Y02A50/386 ,  Y02A50/53

Abstract: Isolated mutant dengue virus E protein variants are disclosed. The variant comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 1 and has one or more amino acid residue substitutions at position corresponding to Asn8 (N8), Arg9 (R9), Val12 (V12) and/or Glu13 (E13). The variant may comprise an amino acid sequence that is at least 90% identical to the SEQ ID NO: 1 and lack an infection-enhancing antibody-binding motif comprising the amino acid sequence of SEQ ID NO: 28 at domain I. An isolated nucleic acid sequence encoding the variant, a plasmid expressing the variant, a plasmid expressing a virus-like particle comprising the variant, a DNA vaccine, and a method of detecting the presence of a dengue virus in a biological sample are also disclosed.

公开(公告)号：US20180009877A1

公开(公告)日：2018-01-11

申请号：US15547523

申请日：2016-02-23

Applicant: Academia Sinica

Inventor： An-Suei YANG ,  Hong-Sen CHEN ,  Ing-Chien CHEN ,  Chao-Ping TUNG ,  Shin-Chen HOU ,  Chung-Ming YU ,  Chi-Kai YANG ,  Yi-Kai CHIU

IPC: C07K16/00 ,  C12N15/10 ,  C07K16/22 ,  C07K16/32

CPC classification number: C07K16/005 ,  C07K16/1018 ,  C07K16/18 ,  C07K16/22 ,  C07K16/245 ,  C07K16/2803 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/32 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C12N15/1037

Abstract: Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, that comprised a plurality of phage-displayed scFvs characterized with (1) a specific CS combination; (2) a specific distribution of aromatic residues in each CDR; and (3) a specific sequence in each CDR. The present scFv library could be used to efficiently produce different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.

公开(公告)号：US09822140B2

公开(公告)日：2017-11-21

申请号：US14406074

申请日：2013-06-03

Applicant: Academia Sinica

Inventor： Shang-Cheng Hung ,  Cheng-Hsiu Chang

IPC: C07H1/00 ,  C07H15/04 ,  C07H23/00 ,  C07H3/06 ,  C07H15/18 ,  C07H15/203

CPC classification number: C07H15/04 ,  C07H1/00 ,  C07H3/06 ,  C07H15/18 ,  C07H15/203 ,  C07H23/00

Abstract: The present invention relates to methods for the synthesis of fondaparinux and intermediates thereto.

公开(公告)号：US09795666B2

公开(公告)日：2017-10-24

申请号：US14619693

申请日：2015-02-11

Applicant: Academia Sinica

Inventor： Pei-Wen Hsiao ,  Chia-Ying Wu ,  Yi-Chun Yeh

IPC: A61K39/145 ,  C12N7/01 ,  A61P31/16 ,  A61K39/42 ,  C12N15/44 ,  A61K39/215 ,  C07K14/005 ,  A61K39/12 ,  C07K16/10 ,  G01N33/569 ,  A61K39/00

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K39/215 ,  A61K2039/5258 ,  C07K14/005 ,  C07K16/1018 ,  C12N2760/16034 ,  C12N2760/16122 ,  C12N2760/16123 ,  C12N2760/16134 ,  C12N2770/20022 ,  C12N2770/20023 ,  C12N2770/20034 ,  C12N2830/006 ,  G01N33/56983 ,  G01N2333/11 ,  G01N2469/10 ,  G01N2469/20

Abstract: Virus-like particles (VLPs) of mammalian-hosted viruses, such as SARS-CoV and influenza viruses, have been recombinantly produced from Vero cells. The VLPs closely emulate the exterior of authentic virus particles and are highly immunogenic. They can elicit not only humoral but also cellular immune responses in a mammal. Compositions and methods related to the VLPs are also described.

公开(公告)号：US20170290886A1

公开(公告)日：2017-10-12

申请号：US15480245

申请日：2017-04-05

Applicant: Academia Sinica

Inventor： Eminy H.Y. LEE ,  Derek Jui-Cheng TAI ,  Yen-Chen LIU ,  Wei-Lun HSU

IPC: A61K38/17 ,  A61K31/191 ,  A61K38/18

CPC classification number: A61K38/1709 ,  A61K31/195 ,  A61K38/18

Abstract: Disclosed herein are methods for treating a neurodevelopmental disorder in a subject in need thereof. The method includes administering to the subject in need thereof an effective amount of a methyl-CpG-binding protein 2 (MeCP2) or a nucleic acid encoding the MeCP2 to alleviate or ameliorate the symptoms associated with the neurodevelopmental disorder. According to preferred embodiments, the MeCP2 has one or more post-translational modifications that result in increased levels of sumoylation, phosphorylation or both, as compared with that of the endogenous MeCP2 in the subject.

公开(公告)号：US20170283878A1

公开(公告)日：2017-10-05

申请号：US15376598

申请日：2016-12-12

Applicant: Academia Sinica

Inventor： Chi-Huey WONG ,  Chung-Yi WU ,  Sarah K.C. CHEUNG ,  Po-Kai CHUANG ,  Tsui-Ling HSU

IPC: C12Q1/68 ,  G01N33/574 ,  G01N33/50

CPC classification number: C12Q1/6886 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/3053 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/734 ,  C07K2317/92 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Y204/01 ,  G01N33/5073 ,  G01N33/57407 ,  G01N33/57492 ,  G01N2333/70585 ,  G01N2333/70596 ,  G01N2333/91097 ,  G01N2405/10 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2800/52

Abstract: The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.